Key result
Rituximab treatment in patients with very high circulating tumor cell counts (>200.0 x 10^9/L) can cause severe, life-threatening infusion-related adverse events due to tumor cell agglutination.
Population
Patients with B-CLL or Richter syndrome with very high numbers of circulating tumor cells (> 200.0 x 10^9/L)
Design
Case_report
Authors
Loading...
Warrants caution with rituximab at high tumor burdens; case report leaves open safe cytoreduction thresholds for prospective study.
Case Report
Rituximab can cause life-threatening tumor cell agglutination and leukostasis in patients with high circulating tumor cell counts, suggesting tumor reduction to < 50.0 x 10^9/L is needed prior to therapy.
Brouwers et al. (2001) conducted a case report in B-CLL or Richter syndrome with high tumor cell counts. Rituximab was evaluated on Severe infusion-related adverse events (tumor cell agglutination/leukostasis). Rituximab treatment in patients with very high circulating tumor cell counts (>200.0 x 10^9/L) can cause severe, life-threatening infusion-related adverse events due to tumor cell agglutination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: